Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

732
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
732
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

664
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
664
Pneumonia IV: Management01:28

Pneumonia IV: Management

699
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
699
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.4K
The pathophysiology of pneumonia involves the following steps:
2.4K
Pneumothorax-II01:27

Pneumothorax-II

786
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M.

Biochemical and biophysical research communications·2018
Same author

Th17 responses to pneumococcus in blood and adenoidal cells in children.

Clinical and experimental immunology·2018
Same author

Induction of endoplasmic reticulum stress by deletion of Grp78 depletes Apc mutant intestinal epithelial stem cells.

Oncogene·2016
Same author

A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.

Mucosal immunology·2015
Same author

Acanthamoeba encephalitis: A Case Report and Review of Therapy.

Surgical neurology international·2014
Same journal

Muc16 contributes to protection against invasive pneumococcal infection originating from nasal colonization.

Microbiology spectrum·2026
Same journal

Tail-specific protease (Tsp)-mediated envelope remodeling and beta-lactam tolerance in <i>Escherichia coli</i>.

Microbiology spectrum·2026
Same journal

Comparative evaluation of EUCAST RAST and QuickMIC for rapid antimicrobial susceptibility testing of carbapenem-resistant organisms directly from positive blood cultures.

Microbiology spectrum·2026
Same journal

Systematic discovery of novel phosphoinositide-binding effectors in <i>Legionella</i> reveals conserved É‘-helical folds.

Microbiology spectrum·2026
Same journal

ZILA-SRM: a probabilistic framework with zero-inflated latent models for robust strain reconstruction from metagenomes.

Microbiology spectrum·2026
Same journal

Emergence and persistence of ESBL- and carbapenemase-producing <i>Klebsiella pneumoniae</i>-related species in Barcelona wastewater treatment plants.

Microbiology spectrum·2026
See all related articles

Related Experiment Video

Updated: Jan 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Pneumococcal Vaccines.

D E Briles1, J C Paton2, R Mukerji1

  • 1Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama.

Microbiology Spectrum
|December 21, 2019
PubMed
Summary
This summary is machine-generated.

Pneumococcal vaccines protect against Streptococcus pneumoniae infections. Alternative strategies, like protein-based vaccines, are needed due to serotype replacement limiting current vaccine effectiveness.

More Related Videos

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.4K

Related Experiment Videos

Last Updated: Jan 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.4K

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Streptococcus pneumoniae (pneumococcus) is a major global cause of bacterial pneumonia, meningitis, and sepsis, particularly in children.
  • Current polysaccharide conjugate vaccines effectively reduce invasive pneumococcal disease but face challenges from serotype replacement.
  • The existence of over 98 pneumococcal serotypes makes expanding current vaccines costly and complex.

Purpose of the Study:

  • To review past and present pneumococcal vaccines.
  • To discuss current protein antigen vaccine candidates.
  • To explore alternative strategies for combating pneumococcal disease.

Main Methods:

  • Literature review of pneumococcal vaccines.
  • Discussion of protein antigens as vaccine candidates.
  • Exploration of alternative vaccine approaches.

Main Results:

  • Polysaccharide conjugate vaccines have reduced disease but serotype replacement is an emerging issue.
  • Protein antigens offer a potential serotype-independent vaccination strategy.
  • Whole cell vaccines are also being considered as an alternative.

Conclusions:

  • Serotype replacement necessitates the development of novel, broadly protective pneumococcal vaccines.
  • Protein-based and whole cell vaccines represent promising avenues for future pneumococcal disease prevention.
  • Continued research into serotype-independent strategies is crucial for global pneumococcal disease control.